BIIB biogen.com Earnings per share growth this year
Biogen Inc. (BIIB) is implementing eco-standards through its Healthy Climate, Healthy Lives program. The neuropharmaceutical sector is characterized by fierce patent battles and R&D risks. The annual earnings per share growth rate, as shown on this GURU.Markets chart, has a parameter value of -18.20. Business success is based on regulatory approvals, insurance reimbursements, and the protection of exclusive drug rights.
Financial and market metric breakdowns for Biogen Inc. (BIIB)
- stock value and consensus price forecast:
- market capitalization data:
- book capitalization information:
- debt and solvency information:
- net income and valuation multiples indicators:
BIIB - Net Profit|Company Profit Forecast Biogen Inc.|BIIB - P/E Multiple|Future Price to Earnings Biogen Idec|BIIB - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Biogen Idec|BIIB - Operating profit EBITDA|Net earnings per one share for the last twelve months Biogen|BIIB - Net earnings per share for the last 12 months|Quarterly EPS earnings growth biogen.com|BIIB - Earnings per share growth in current year|Expected earnings per share trend next year Biogen Inc.
Summary company analysis:BIIB - Biogen Inc
The diversification of the neurobiological drug portfolio of Biogen Inc. (BIIB) reduces dependence on the success of individual trials, which is directly reflected in the year-over-year EPS dynamics. This indicator measures the annual growth rate of net income per share, allowing investors to assess the financial stability of the business and balance current risks between stable growth and capital stagnation.
Direct competitors
Earnings per share growth rate in current year Neurocrine (NBIX)|Earnings per share growth in current year Regencell|Earnings per share growth this year AXSM (Axsome Corp)|Net earnings per share growth this year ACAD (ACADIA Pharmaceuticals)|XENE (xenon-pharma.com) - Earnings per share increase in current year|Earnings growth in current year VKTX (Viking Therapeutics, Inc.)|Expected net earnings per share growth this year Supernus Pharmaceuticals, Inc. (SUPN)|CPRX - Earnings per share growth in current year|DNLI (Denali Corp) - Earnings per share growth this year|HRMY: Earnings growth in current year|Net earnings per share growth this year biohavenpharma.com|Net earnings per share growth this year AMLX|Trevi Therapeutics Inc (TRVI) - Expected net earnings per share growth this year|Earnings growth in current year PRAX|Earnings per share growth in current year AVXL (Anavex Life Sciences Corp)|Earnings growth in current year CBLL (CeriBell, Inc.)|Expected net earnings per share growth this year prothena.com (PRTA)|Alector Therapeutics - Earnings growth in current year|Expected net earnings per share growth this year Annexon Biosciences ANNX|OMER: Earnings growth in current year|NGNE (Neurogene Therapeutics) - Earnings per share growth in current year|Earnings per share growth in current year AC Immune|Earnings per share growth this year VYGR (voyagertherapeutics.com)|Earnings growth in current year NMRA|SCLX - Earnings per share growth rate in current year|Tevogen Bio Holdings, Inc. - Net earnings per share growth this year|Earnings growth in current year Alpha Cognition Inc ACOG|CGTX - Earnings per share growth in current year|Earnings per share increase in current year IKT (inhibikase.com)|Cassava Sciences (SAVA) - Earnings per share growth in current year|Earnings per share growth rate in current year Assertio (ASRT)|COYA (Coya Therapeutics Inc) - Earnings growth in current year|Earnings per share growth in current year VTGN|Earnings growth in current year OVID|Expected net earnings per share growth this year acumenpharm.com|Earnings per share growth in current year CervoMed CRVO|Alterity Therapeutics Ltd. (ATHE) - Earnings per share growth rate in current year|Clene Nanomedicine - Earnings growth in current year|Net earnings per share change in current year PepGen Inc. (PEPG)|JUNS: Earnings growth in current year|Earnings per share growth rate in current year relmada.com (RLMD)|Earnings per share growth in current year Annovis Bio|Earnings per share growth this year GRCE (Grace Tx)|Net earnings per share growth this year AIFF (Firefly Neuroscience Inc)|KLTO (anewmeds.com) - Earnings per share increase in current year|Earnings growth in current year NRSN (NeuroSense Therapeutics Ltd.)|Expected net earnings per share growth this year revivapharma.com (RVPH)|MTVA - Earnings per share growth in current year|NRXS (NeurAxis Inc.) - Earnings per share growth this year|HSDT: Earnings growth in current year|Net earnings per share growth this year Passage Bio|Net earnings per share growth this year NEUP|minervaneurosciences.com (NERV) - Expected net earnings per share growth this year|Earnings growth in current year ATHA|Earnings per share growth in current year ADXN (Addex Therapeutics Ltd.)|Earnings growth in current year ALZN (Alzamend Neuro)|Expected net earnings per share growth this year Cyclerion Therapeutics Inc. (CYCN)|Protagenic - Earnings growth in current year|Expected net earnings per share growth this year Pasithea Therapeutics KTTA|CRGT: Earnings growth in current year|ATXI (Avenue Therapeutics Inc.) - Earnings per share growth in current year|Earnings per share growth in current year Brainstorm Cell Therapeutics, Inc.|Earnings per share growth this year CARA (Cara Therapeutics Inc)|Earnings growth in current year CHRO|ELYM - Earnings per share growth rate in current year|Intra-Cellular Therapies, Inc. - Net earnings per share growth this year|Earnings growth in current year Longboard Pharmaceuticals Inc LBPH|MRNS - Earnings per share growth in current year|Earnings per share increase in current year NKGN (NKGen Biotech Corp)|NeuroBo Pharmaceuticals (NRBO) - Earnings per share growth in current year|Earnings per share growth rate in current year sagerx.com (SAGE)|SNPX (Synaptogenix) - Earnings growth in current year|Earnings per share growth in current year TRVN|Earnings growth in current year VIGL|Expected net earnings per share growth this year anewmeds.com|Earnings per share growth in current year Cerevel Therapeutics CERE
